The next few decades will be a slow process of proving that the SENS model works well, and that other models don't work well, when it comes to reversing age-related disease and producing rejuvenation in older individuals. There will be reluctant acceptance on the part of the mainstream, and development will largely shift to what works, slowly and late.
This can be seen in its infancy today in the rapid progression of work on senolytics. In just six years, clearance of senescent cells has already far outpaced the past few decades of work on calorie restriction mimetics, producing more impressive and reliable results in animal studies. Things that work are hard to ignore, so everyone now retrofits senescent cells into their models of aging and development - that didn't include them seven years ago - and continues to try to ignore the rest of the SENS to-do list. Senolytics development is becoming heavily funded, and is on its way to the clinic.
This process will reoccur every time the poorly funded bootstrapping side of the SENS research community manages to advance to the point of a technology demonstration, which happened in 2011 for cellular senescence. Expect this to happen for cross-link breaking sometime in the next few years, which will be just as impressive for cardiovascular aging as senescent cell clearance is for inflammatory/fibrotic conditions of aging.
One would hope that at some point, some people involving in this process make the realization that they could just implement the rest of SENS themselves, with the successful biotech company they are involved in. There are a number of existing companies/groups where this may well happen, if they grow sufficiently large.